ADMA Biologics (ADMA) to Release Earnings on Thursday

ADMA Biologics (NASDAQ:ADMA) will announce its earnings results after the market closes on Thursday, August 8th. Analysts expect the company to announce earnings of $0.08 per share for the quarter. ADMA Biologics has set its FY 2024 guidance at EPS and its FY 2025 guidance at EPS.Investors that are interested in participating in the company’s conference call can do so using this link.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings data on Thursday, May 9th. The biotechnology company reported $0.08 earnings per share for the quarter, topping analysts’ consensus estimates of $0.05 by $0.03. ADMA Biologics had a negative net margin of 1.29% and a positive return on equity of 17.24%. The company had revenue of $81.90 million for the quarter, compared to analysts’ expectations of $77.28 million. During the same quarter last year, the company earned ($0.03) earnings per share. The firm’s revenue for the quarter was up 43.9% on a year-over-year basis. On average, analysts expect ADMA Biologics to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

ADMA Biologics Stock Up 4.6 %

ADMA stock traded up $0.52 during midday trading on Tuesday, reaching $11.82. 1,557,202 shares of the company were exchanged, compared to its average volume of 2,910,511. The company has a debt-to-equity ratio of 0.91, a quick ratio of 1.86 and a current ratio of 5.21. ADMA Biologics has a 1-year low of $3.06 and a 1-year high of $14.03. The stock’s 50-day simple moving average is $11.46 and its 200 day simple moving average is $8.13. The company has a market cap of $2.74 billion, a price-to-earnings ratio of -565.00 and a beta of 0.55.

Insider Activity

In related news, CEO Adam S. Grossman sold 100,000 shares of ADMA Biologics stock in a transaction on Friday, June 14th. The shares were sold at an average price of $10.72, for a total value of $1,072,000.00. Following the transaction, the chief executive officer now directly owns 2,081,475 shares in the company, valued at approximately $22,313,412. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 3.70% of the company’s stock.

Analyst Ratings Changes

A number of analysts have weighed in on ADMA shares. Mizuho raised their price objective on shares of ADMA Biologics from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Thursday, June 20th. HC Wainwright lifted their target price on shares of ADMA Biologics from $7.50 to $10.00 and gave the company a “buy” rating in a report on Friday, May 10th. Raymond James lifted their target price on shares of ADMA Biologics from $8.00 to $10.00 and gave the company a “strong-buy” rating in a report on Friday, May 10th. Finally, Cantor Fitzgerald lifted their target price on shares of ADMA Biologics from $10.00 to $15.00 and gave the company an “overweight” rating in a report on Tuesday, July 9th. One analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, ADMA Biologics currently has an average rating of “Buy” and a consensus price target of $12.25.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.